RMC-5127, a first-in-class, orally bioavailable mutant- selective RASG12V( ON) inhibitor is central nervous system (CNS)-penetrant and demonstrates antitumor activity in a preclinical intracranial xenograft model

被引：3
|
作者：
Chen, Zhe
Eriksson, Andre
Lee, Bianca
Dinglasan, Jay
Montazer, Nilufar
Cregg, Jim
Edwards, Anne
Sanders, Kate
Smith, Jacqueline A.
Wildes, David
Singh, Mallika
Wang, Zhican
Jiang, Jingjing
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-3340
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3340
引用
收藏
页数：2
相关论文
共 1 条
  • [1] RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models
    Menard, Marie J.
    Chow, Christopher
    Chen, Kevin
    Blaj, Cristina
    Shifrin, Nataliya Tovbis
    Courtney, Haley
    Nasholm, Nicole M.
    Pham, Anna
    Kumamoto, Alice
    Ganesh, Swetha
    Evans, James W.
    Lawrence, Lindsey
    Vonmelchert, Brian
    Kwok-Parkhill, Amy C.
    Jiang, Jingjing
    Knox, John E.
    Smith, Jacqueline
    Quintana, Elsa
    CANCER RESEARCH, 2023, 83 (07)
1